Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and…
Initial data expected in first half of 2024NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)…
Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational…
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the…
Cash balance of $18.5 million as at March 31, 2023Revenue of $3.95 million (vs 2022: $2.3 million, an increase of…
New Product Showing Encouraging Early ResultsSHERMAN OAKS, CA / ACCESSWIRE / July 31, 2023 / Avenir Wellness Solutions, Inc. (OTC:CURR)…
LUND, SE / ACCESSWIRE / July 31, 2023 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Tumorad® into clinicJANUARY - JUNE IN BRIEFNet…
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitisConfirmed seven total events of non-occlusive/occlusive…
89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their…
LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an…